PPARD and colorectal carcinoma: Together, these findings hold promise for the use of fasting regimens and PPARδ agonists in ameliorating intestinal dysfunction and improving the tolerability and efficacy of current chemotherapies [191,192] but, conversely, advocate the evaluation of PPARδ antagonists in the CRC setting—particularly for obese patients.